Heron Therapeutics (HRTX) Q1 2026 earnings review
Acute Care Grows, But Oncology's Collapse Derails The Quarter
Heron's Q1 results reveal a broken bridge. Management has long touted the Oncology franchise (CINVANTI) as the stable cash-cow funding the high-growth Acute Care rollout. But in Q1, Oncology revenue plunged 26% YoY, dragging total revenue down 11% to $34.7M and pushing Adjusted EBITDA back into the red (-$0.7M). While ZYNRELEF (+27%) and APONVIE (+50%) continue to grow, their absolute dollar gains couldn't offset CINVANTI's bleeding. Management blamed weather and seasonality, reaffirming FY26 guidance of $173-$183M, which implies a massive, high-risk acceleration in Q2-Q4 that strains credibility.
🐂 Bull Case
APONVIE demand units surged 68% YoY, and ZYNRELEF target accounts under the IGNITE program grew 111%. The underlying unit demand for the growth engines remains intact.
APONVIE's permanent J-code (J8502) went live on April 1, 2026. Combined with ZYNRELEF's existing J-code and NOPAIN Act coverage, reimbursement barriers are rapidly vanishing.
🐻 Bear Case
CINVANTI revenue fell 20% YoY. If price erosion outpaces unit growth in the Oncology segment, Heron loses the financial foundation required to fund its Acute Care sales expansion.
To hit the $178M midpoint of FY26 guidance, Heron must average nearly $48M in revenue per quarter for the rest of the year—a massive jump from Q1's $34.7M.
⚖️ Verdict: 🔴
Bearish. Reversing margins and a 20% drop in your anchor product (CINVANTI) cannot be ignored. The company needs flawless execution and zero competitive pressure to hit its aggressive full-year targets.
Key Themes
CINVANTI: Narrative vs. Data
Reversing. In previous quarters, management repeatedly characterized CINVANTI as a 'stable', 'resilient' anchor that would see volume growth offset price erosion. The Q1 data directly contradicts this: CINVANTI net revenue dropped 20.2% YoY to $20.5M. This is a severe break in trend that threatens the company's entire self-funding growth strategy.
Margin Compression Reversal
Reversing. After quarters of improving operational efficiency, Gross Margin compressed to ~69% (down from 78% in 25Q1). Management cited 'higher-cost CINVANTI inventory' and expects this pressure to persist for the next two quarters. Consequently, Adjusted EBITDA turned negative (-$0.7M) for the first time since 2024.
The Guidance Hockey Stick
Stable (but problematic). Management reaffirmed the $173M-$183M FY26 revenue guidance. With only $34.7M banked in Q1, Heron needs $143.3M over the next three quarters (avg. $47.7M/quarter). Considering Q1 revenue actually declined sequentially from Q4's ~$40M, the required acceleration represents massive execution risk.
APONVIE Growth & J-Code Activation
Accelerating. APONVIE net revenue hit $3.4M (+50% YoY), with demand units up 68%. The activation of its permanent product-specific J-code (J8502) on April 1, 2026, alongside its inclusion as the only FDA-approved IV NK-1 antagonist in the Fifth Consensus Guidelines for PONV, provides structural tailwinds for H2 2026.
ZYNRELEF Expansion & NOPAIN Macro
Stable. ZYNRELEF revenue grew 27% YoY to $10.2M. The IGNITE alignment program drove a 111% growth in target accounts by end-of-2025 and expanded by another 40% in January 2026. The macro implementation of the NOPAIN Act continues to provide a predictable reimbursement environment across 110 million commercial lives.
Sales Force Expansion Underway
Accelerating. Heron is actively recruiting for a planned Q3 2026 sales force expansion. The strategy is to increase account depth and coverage across both Acute Care and Oncology. If the ROI holds, this could provide the late-year revenue surge needed to approach guidance.
Other KPIs
Down sequentially from $55M+ levels seen in late 2025. With Adjusted EBITDA turning negative in Q1, cash burn is back on the table. The company must return to positive cash generation quickly to avoid liquidity concerns.
Stable. SG&A and R&D combined increased only 5.6% YoY. Management is maintaining disciplined cost control; the net loss (-$8.1M) was entirely driven by the revenue miss and gross margin compression, not bloated spending.
Guidance
Accelerating (Implied). The midpoint ($178M) implies ~15% YoY growth over FY25's ~$155M. Given Q1's -10.8% YoY decline, the remaining three quarters must average over 25% YoY growth to mathematically achieve this target.
Accelerating (Implied). Reaffirmed. Since Q1 was -$0.7M, the company needs to generate roughly $15.7M in Adjusted EBITDA over the next three quarters to hit the midpoint. This heavily relies on gross margins recovering from the current CINVANTI inventory headwind.
Key Questions
Bridging the Guidance Gap
With Q1 revenue down 11% YoY and trailing the implied run-rate significantly, what exact catalysts in Q2 and Q3 give you confidence in reaffirming the $173-$183M full-year target?
CINVANTI Floor
CINVANTI fell 20% YoY in Q1. Is this the bottom for price erosion and volume declines, or should we model the Oncology segment as a structurally shrinking asset moving forward?
Margin Recovery Timeline
You cited higher-cost CINVANTI inventory pressuring gross margins for 'the next two quarters.' Can you quantify the basis point impact and confirm exactly when we should expect margins to return to the mid-70s?